Devices › Aortic valve, prosthesis, percutaneously delivered
Device brand name · Aortic valve prosthesis percutaneously delivered
Edwards SAPIEN XT Transcatheter Heart Valve: medical device reports filed with FDA
2,249 reports name it, 2014–2026. Manufacturer given most often on reports: Edwards Lifesciences. Product code NPT.
- 2,249
- device reports naming the brand
- 0% of all MAUDE reports · about 187 a year
- 48
- reports, 12 months to August 2026
- 72 in the 12 months before
- 2.4%
- classified as malfunction
- 15.2% across the product code
- 7.6%
- classified as death, as reported
- 170 reports · not verified by FDA
2,249 medical device reports received by FDA name the brand "Edwards SAPIEN XT Transcatheter Heart Valve" (aortic valve prosthesis percutaneously delivered); the manufacturer given most often on reports is Edwards Lifesciences; received from July 2014 to August 2026. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
48 reports arrived in the 12 months to August 2026, down 33% from 72 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (90%), death (7.6%) and malfunction (2.4%); across all aortic valve, prosthesis, percutaneously delivered reports (product code NPT) death is recorded in 10.1% and malfunction in 15.2%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are malposition of device (20%), perivalvular leak (18.5%) and degraded (9.2%). The patient problems coded most often are aortic regurgitation, complete heart block and rupture. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 79,063 reports carrying product code NPT. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Malposition of device | 450 | 20% | 5% |
| Perivalvular leak | 417 | 18.5% | 13% |
| Degraded | 208 | 9.2% | 3% |
| Calcified | 150 | 6.7% | 2.8% |
| Device dislodged or dislocated | 128 | 5.7% | 8.4% |
| Insufficient device problem information | 114 | 5.1% | 10.2% |
| Leak/splashthe device leaked | 83 | 3.7% | 1% |
| Migration or expulsion of device | 75 | 3.3% | 2.4% |
| Fluid/blood leak | 72 | 3.2% | 2.7% |
| Gradient increase | 63 | 2.8% | 3.2% |
| Incomplete coaptation | 37 | 1.6% | 0.7% |
| Unintended movement | 23 | 1% | 0.3% |
| Device stenosis | 19 | 0.8% | 2.9% |
| Device slipped | 11 | 0.5% | 0.1% |
| Difficult to open or close | 10 | 0.4% | 1% |
| Intravalvular regurgitation | 10 | 0.4% | 3% |
| Positioning problem | 9 | 0.4% | 0.7% |
| Device operates differently than expectedthe device behaved unexpectedly | 7 | 0.3% | 0.2% |
| Activation, positioning or separation problem | 5 | 0.2% | 0.2% |
| Device-device incompatibility | 5 | 0.2% | 0.1% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Aortic regurgitation | 460 | 20.5% |
| Complete heart block | 220 | 9.8% |
| Rupturethe device burst | 146 | 6.5% |
| Aortic valve stenosis | 118 | 5.2% |
| Not applicable | 111 | 4.9% |
| Injurya physical injury | 106 | 4.7% |
| Occlusion | 101 | 4.5% |
| Infarction, cerebral | 97 | 4.3% |
| Arrhythmia | 94 | 4.2% |
| Dyspneashortness of breath | 94 | 4.2% |
| Aortic insufficiency | 92 | 4.1% |
| Stenosis | 60 | 2.7% |
| Deaththe patient died; cause not stated by this term | 58 | 2.6% |
| Heart failure/congestive heart failure | 57 | 2.5% |
| Stroke/cva | 48 | 2.1% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Edwards SAPIEN XT Transcatheter Heart Valve | Product code NPT | All MAUDE reports |
|---|---|---|---|
| Reports | 2,249 | 79,063 | 26,136,888 |
| Share of that pool | — | 2.8% | 0% |
| Classified as death, per 1,000 reports | 76 | 101 | 9 |
| Classified as injury | 90% | 74.6% | 36.2% |
| Classified as malfunction | 2.4% | 15.2% | 62.3% |
| Filed by the manufacturer | 99.9% | 99.6% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code NPT
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Edwards SAPIEN 3 Transcatheter Heart valve | 8,127 | 668 | 9.2% |
| Evolut R Transcatheter Aortic Valve | 6,444 | 521 | 9.6% |
| Evolut Pro Plus Valve | 5,873 | 780 | 12.8% |
| Evolut Fx Valve | 5,267 | 851 | 14.1% |
| Evolut Pro Transcatheter Aortic Valve | 3,668 | 422 | 11% |
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve | 3,737 | 714 | 14% |
| Evolut Fx Plus Valve | 3,448 | 2,316 | 8.9% |
| Edwards COMMANDER DELIVERY SYSTEM | 3,105 | 368 | 12.3% |
| Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve | 2,885 | 1,128 | 11.6% |
| Evolut Fx Dcs | 2,570 | 860 | 10.8% |
| Navitor Vision | 2,045 | 1,258 | 6.4% |
| SAPIEN 3 Transcatheter Heart Valve | 2,196 | 419 | 6% |
| Corevalve Transcatheter Aortic Valve | 1,669 | 60 | 9.6% |
| Edwards Sapien Transcatheter Heart Valve | 1,947 | 7 | 14.3% |
| Navitor Transcatheter Aortic Valve | 1,382 | 245 | 9% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Edwards SAPIEN XT Transcatheter Heart Valve reports
How many FDA reports name Edwards SAPIEN XT Transcatheter Heart Valve?
2,249 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 48 in the latest 12 months.
What kinds of events are reported?
injury (90%), death (7.6%) and malfunction (2.4%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
malposition of device (20%), perivalvular leak (18.5%), degraded (9.2%), calcified (6.7%) and device dislodged or dislocated (5.7%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (99.9%) and voluntary reports (0%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Edwards SAPIEN XT Transcatheter Heart Valve was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.